Midday on the fly: SuperValu gains, ViroPharma loses
Stocks on Wall Street were lower at midday, threatening to extend the market's slide to a fifth straight session.
Stock futures traded slightly above fair value in the early part of the pre-market session Tuesday but eventually closed flat. The futures action led to a relatively quiet open where stock prices hovered near the flat line for the opening minutes of the session. After the wholesale inventories report for February the averages began to weaken. The selling accelerated in the last hour, pushing each of the major indices to session lows and down over 1%.
Near noon, the Dow was down 158.14, or 1.22%, to 12,771.45; the Nasdaq was down 44.90, or 1.47%, to 3,002.18; and the S&P 500 was down 19.25, or 1.39%, to 1,362.95.
Economic events
Domestically, the NFIB small business optimism index fell to 92.5 in March. U.S. wholesale inventories rose 0.9% in February, versus analysts' estimates of an increase of 0.5%. The Labor Department said employers posted 3.5 million job openings in February, up just barely from a revised 3.48 million in January.
Internationally, China reported an unexpected trade surplus in March, as imports rose 5.3% and exports increased 8.9% from a year earlier for a surplus of $5.35 billion. Also, Spain's borrowing costs rose again to hit their highest levels since December.
Company news
Best Buy (BBY) announced its CEO Brian Dunn resigned, citing a mutual agreement that new leadership was needed at the company. Shares spiked initially but then reversed to be down 3.5% near noon.
Sony (SNE) more than doubled its projected annual loss to $6.4 billion as it writes off deferred tax credits, sending its stock down over 10%.
Major movers
Among the notable gainers were X-Rite Incorporated (XRIT), up 39%, after Danaher (DHR) agreed to acquire the company for $5.55 per share, and SuperValu (SVU), up 9%, following quarterly adjusted earnings and guidance that beat estimates. Noteworthy losers included ViroPharma (VPHM), down 16.5%, after Akorn (AKRX), Watson (WPI) and a third company gained approval and launched generic versions of its Vancocin drug, and Optimer (OPTR), down about 10%, following a warning that first-quarter revenue will miss consensus.
MORE ON MSN MONEY
DATA PROVIDERS
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
Japanese stock price data provided by Nomura Research Institute Ltd.; quotes delayed 20 minutes. Canadian fund data provided by CANNEX Financial Exchanges Ltd.
LATEST POSTS
The market's cheap money addiction is laid bare. No one knows how it will end.
FIDELITY VIEWPOINTS
- How to sell covered calls - Fidelity Investments
- Savvy year-end tax moves to consider now - Fidelity Investments
- Seven ways to prepare for tax changes
- Five reasons an annual review is crucial - Fidelity Investments
- Take a look at mid caps now - Fidelity Investments
- State of the sector: Health care - Fidelity Investments
VIDEO ON MSN MONEY
ABOUT
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.
